Data compiled by Redley Lamar · ChainSifter Intelligence
2Suppliers
0Customers
2Debt Items
0Related Chains
Source-Backed Evidence Depth
Amylyx Pharmaceuticals, Inc. (AMLX) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.
5Total relationships
2Distinct source URLs
5High confidence
0.860Average confidence
2026-10-28Latest database update
ChainSifter does not infer unreported suppliers, customers, ownership, acquisitions, debt exposure, revenue dependency, or future supply-chain events on this public page.
Amylyx Pharmaceuticals, Inc. Suppliers
Ticker
Name
Confidence
Evidence
CMOS
CMOS
80%
expenses incurred under agreements with CROs, CMOs, as well as investigative sites and consultants that conduct our clinical trials
CROS
CROS
80%
expenses incurred under agreements with CROs, CMOs, as well as investigative sites and consultants that conduct our clinical trials
Amylyx Pharmaceuticals, Inc. Customers
No clients on recordAmylyx Pharmaceuticals, Inc. does not appear to disclose named customer relationships in its verified regulatory filings. Many companies do not publicly name customers in regulatory disclosures.
Amylyx Pharmaceuticals, Inc. Debt Obligations
Instrument
Description
Confidence
Evidence
AMLX-DEBT-7729
Xbrl Convertible
90%
xbrl convertible detail from xbrl 2022-12-31.
AMLX-DEBT
Debt stack $5.6M
90%
Market cache reports total debt of $5.6M.
Amylyx Pharmaceuticals, Inc. Acquisitions
No acquisitions on recordNo completed or pending acquisitions found in our database for Amylyx Pharmaceuticals, Inc..
Amylyx Pharmaceuticals, Inc. Ownership
Holder
Name
Confidence
Evidence
AMLX-OWNER-FMR-LLC
FMR LLC
90%
13F overlay lists FMR LLC as top holder; 174 tracked holders.
Amylyx Pharmaceuticals, Inc. Extended Supply Chain Network
No secondary connectionsNo correlated companies found through shared supply chain relationships.
